1. BioLife Solutions Investor Presentation : May 2023
1
NASDAQ: BLFS
Tooling Up
Cell & Gene Therapies
Investor Presentation
May 2023

2. BioLife Solutions Investor Presentation : May 2023
2
Safe Harbor Statement
NASDAQ:
BLFS
Cautions Regarding Forward Looking Statements
Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the Company, the Company's ability to
implement its business strategy (including with respect to any strategic alternatives) and anticipated business and operations, the potential utility of and market for the
Company's products and services, including, but not limited to, the adoption of the Company’s products for new clinical candidates in connection with expected clinical trials, and
the Company’s ability to cross sell its products and services, guidance for financial results for 2023 and 2024, including regarding potential revenue growth and changes in
product mix of total revenue and gross margin, the Company’s ability to realize reductions in expenses as a result reductions in supply and shipping costs, the Company's
anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, regulatory approvals and/or
commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be
deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and
assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, market adoption of the
Company’s products, the ability of the Company to continue to implement its business strategy (including with respect to any strategic alternatives), uncertainty regarding third-
party market projections, market volatility, competition, litigation, the impact of the COVID-19 pandemic and supply chain issues, unexpected costs, charges or expenses
resulting from our acquisitions, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time,
including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking
statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Non-GAAP Measures of Financial Performance:
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of
financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net
income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial
measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as
substitutes for the comparable financial measures prepared in accordance with GAAP.

3. BioLife Solutions Investor Presentation : May 2023
3
Growth Catalysts
Captive marquee base of CGT customers
Directly and indirectly supplying majority of global pharma companies
Proprietary biopreservation media embedded in > 630 customer clinical applications & 140
using Sexton cell processing tools
CGT outlook as dominant treatment modality
Currently serving large disease states; cell processing tools embedded in 14 approved
therapies
Expecting continued expansion of indications, additional geographic approvals and
prioritization in the treatment regimen to 1st or 2nd line therapies
Revenue mix shift over next 3-5 years
2022 actual: recurring* high margin revenue ~ 60% of total
2025 estimate: recurring* high margin revenue ~ 70% of total
*Recurring = Cell Processing Platform & Storage & Storage Services
Platform

4. BioLife Solutions Investor Presentation : May 2023
4
Synergies
Q1 2023 Revenue
Segment Revenue ($millions) Q1 2023 Q1 2022
YoY
Growth
Q4 2022
QoQ
Growth
Cell Processing
(Biopreservation media & Sexton)
$19.0 $14.9 28% $20.2 (6)%
Freezers & Thaw
(CBS, Stirling & ThawSTAR®)
$13.0 $15.3 (15)% $17.4 (25)%
Storage & Cold Chain
(SciSafe & evo® Cold Chain)
$5.7 $6.0 (5)% $6.7 (15)%
Total $37.7 $36.2 4% $44.3 (15)%

5. BioLife Solutions Investor Presentation : May 2023
5

6. BioLife Solutions Investor Presentation : May 2023
6

7. BioLife Solutions Investor Presentation : May 2023
7

8. BioLife Solutions Investor Presentation : May 2023
8
Reconfirming 2023 Revenue Guidance
• Approximately 45% of 2023 total revenue is expected in the first half of the year and approximately 55% in the second half of the year, reflecting typical seasonality.
• Revenue guidance for 2023 does not include any COVID related revenue.
• Management expects full year positive Adjusted EBITDA and Adjusted EBITDA growth in 2023.
Segment Revenue ($millions)
Low
Revenue
High
Revenue
Low
Growth
High
Growth
Ex-COVID
Low
Growth
Ex-COVID
High
Growth
Cell Processing
(Biopreservation media & Sexton)
$89.0 $93.0 30% 35% N/A N/A
Freezers & Thaw
(CBS, Stirling & ThawSTAR®)
$72.5 $79.0 9% 18% 13% 23%
Storage & Cold Chain
(SciSafe & evo® Cold Chain)
$26.5 $30.0 0% 13% 64% 86%
Total $188.0 $202.0 16% 25% 26% 35%

9. BioLife Solutions Investor Presentation : May 2023
9
Focus & Strategy
Protect and grow core media franchise
Optimize supply chain and manufacturing
operations across all platforms
Relentless focus on quality to ensure stellar
customer experiences
Leverage reputation and relationships to cross-
sell entire product portfolio
Explore alternatives to divest freezer
businesses to refocus portfolio on high margin,
recurring revenue
Q1 2023 HIGHLIGHTS
~28%
CELL PROCESSING Y/Y
REVENUE GROWTH
~800
EMBEDDED IN
CUSTOMER CLINICAL
APPLICATIONS
>4,200
INDIRECT CUSTOMERS
197
NEW CUSTOMERS

10. BioLife Solutions Investor Presentation : May 2023
10
High-Growth Bioproduction Tools Business
2022 2023Low 2023High
Total Growth 36% 16% 25%
Ex-COVID Organic Growth 30% 26% 35%
= Q1 2023 Actual
= FY 2023 Low Estimate
$0
$50
$100
$150
$200
2021 2022 2023 Est
Total Revenue ($mm)
= FY 2023 High Estimate

11. BioLife Solutions Investor Presentation : May 2023
11
Three Complementary Value Platforms
2022 2023Low 2023High 2022 2023Low 2023High 2022 2023Low 2023High
Total Growth 53% 30% 35% 18% 9% 18% 51% 0% 13%
Ex-COVID Organic Growth 45% N/A N/A 5% 13% 23% 12% 64% 86%
FY 2023 Low Estimate
FY 2023 High Estimate
$0
$10
$20
$30
$40
$50
$60
$70
$80
$90
$100
Cell Processing Freezers & Thaw Storage & Storage Services
Total Revenue ($mm)
2021 2022 2023 FY Est
Q1 2023 Actual

12. BioLife Solutions Investor Presentation : May 2023
12
Q1 2023 Recurring vs. Equipment Revenue
65%
35%
Recurring
Equipment

13. BioLife Solutions Investor Presentation : May 2023
13
2022 Revenue Channels
Cell Processing Freezers & Thaw Storage & Storage Services
62%
38%
74%
26% 19%
81%
Direct Distributor

14. BioLife Solutions Investor Presentation : May 2023
14
Q1 2023 Revenue Channels
Cell Processing Freezers & Thaw Storage & Storage Services
65%
35%
7…
30% 30%
70%
Direct Distributor

15. BioLife Solutions Investor Presentation : May 2023
15
BioLife Solutions Product Portfolio
Cell Processing Storage and Services Freezing and Thawing

16. BioLife Solutions Investor Presentation : May 2023
16
2013 2021
Accolades
2020
2015 2022

17. BioLife Solutions Investor Presentation : May 2023
17
Regenerative
Medicine Market

18. BioLife Solutions Investor Presentation : May 2023
18
2,093 Active Regenerative Medicine Clinical Trials
• Cell therapies: 46%
• Cell-based immuno-oncology (CBIO): 34%
• Gene therapies: 18%
• Tissue-engineered therapies: 2%
• Industry-sponsored: 48%
• Academic- and government-sponsored: 52%
Source: Alliance for Regenerative Medicine 1H 2022 Report
Active Clinical Trials by Sponsor and Phase Active Clinical Trials by Therapy 2022H1

19. BioLife Solutions Investor Presentation : May 2023
19
Regenerative Medicine Sector Snapshot
• Three new gene therapies approved in 2022 – a record for the sector
• 3 CAR-T therapies expanded as treatment options vs. different
cancers — with 2 approved as earlier-line treatments
• First-ever allogeneic (“off-the-shelf”) T-cell therapy approved globally
• Up to 10 additional regulatory decisions this year on cell and
gene therapies
Source: Alliance for Regenerative Medicine April 2023 Sector Snapshot
Growing Approval Pipeline
Active Development Landscape
2022 Highlights

20. BioLife Solutions Investor Presentation : May 2023
20
Biopreservation Challenges
Causes of Reduced Biologic Potency
CAR T and other cell therapies MUST be kept alive during manufacturing, storage
and shipping to maintain biologic potency
Poor Preservation Temp Excursions Mechanical Shock
Survival
How Long
Viability
How Many
Function
How Well
As Ex Vivo Time Increases, So Does Risk

21. BioLife Solutions Investor Presentation : May 2023
21
Use of
suboptimal
bioproduction
tools
Cell or gene
therapy exposed to
detrimental
environmental
conditions in
preservation,
storage, transport,
thawing
Less
viable/healthy
dose
administered
Lack of desired
therapeutic
response by
the patient
Risk of
non-reimbursement
by payer
THERAPEUTIC AND ECONOMIC RISK CASCADE
Customer Reimbursement Environment
“Pay for response/cure” paradigm
Paid out over time only if initial and durable response to treatment is confirmed
Increased economic risk for our customers
+ =
+ +

22. BioLife Solutions Investor Presentation : May 2023
22
Momentum with Global CGT Customers
Used in or planned to be
used in > 630 customer
clinical applications
Embedded in 13 approved
CGT products, with ~ 10
additional therapies
expected regulatory filing
submissions in 2023
Biopreservation Media
Products
Cold Chain Management
Products
Currently supporting 4 of
the 6 currently approved
CAR T-cell therapies
By mid 2024, expect the
evo platform to be used
in all currently approved
CAR T-cell therapies
Sexton Cell Processing
Tools
Used in or planned to be
used in > 140 customer
clinical applications
Embedded in 3 approved
CGT products

23. BioLife Solutions Investor Presentation : May 2023
23
US FDA Master File Cross References for Media Use
27
47
57
69
79
63
80
20
2016 2017 2018 2019 2020 2021 2022 Q1 2023

24. BioLife Solutions Investor Presentation : May 2023
24
Products and
Services Portfolio

25. BioLife Solutions Investor Presentation : May 2023
25
Our Solutions Embedded in Customer CGT Workflow
evo® DI Dry Ice Smart Shippers
evo® LN2 Smart Shippers
evoIS™ Web Application
ModPak™ Packout Kit
BioT™
Intra-campus Transport
CryoStor® Freeze Media
BloodStor® Media
HypoThermosol® FRS
Storage & Shipping Media
nLiven PR™ Platelet Lysate
Stemulate™ Platelet Lysate
CellSeal® Cryogenic Vials
Signata CT-5TM Closed
Fluid Management System
CellSeal® Connect
CellSeal® RF Sealer
CellSeal® AF-500
Automated Fill & Seal
CBS Cryogenic Solutions
Intellirate ™ Controlled
Rate Freezers
Standard, Expanded,
and High-Capacity
Isothermal LN2 Freezers
Standard LN2 Freezers
Stirling Ultracold ® ULT
Freezers
SciSafe® Storage Services
evo® DI Dry Ice Smart Shippers
evo® LN2 Smart Shippers
evoIS™ Web Application
ModPak™ Packout Kit
BioT™ Intra-campus Transport
ThawSTAR®
Water-free, automated
thawing systems for
bags and vials
Safely store and transport
harvested cells from
collection to processing
Stabilize starting materials
through expansion and
cryopreservation
Minimize variability
between samples to
ensure batch consistency
& maximum recovery
Ensure maximum viability
& efficacy of frozen
samples through
optimized cooling rate
Reliably maintain stable
minimum safe storage
temperature to avoid loss
of viability
Ensure the integrity &
security of the chain of
custody with temperature
monitoring and traceability
Safeguard consistent
sample viability while
minimizing contamination
risk during thawing
Collection Formulation Fill & Packaging Controlled-Rate Freezing Storage Cold Chain Thawing

26. BioLife Solutions Investor Presentation : May 2023
26
Cell Processing Platform

27. BioLife Solutions Investor Presentation : May 2023
27
CryoStor® Freeze Media - Proprietary
Improved cell viability and functional recovery
compared to commercial and home-brew
alternatives in numerous cell types
Formulated to mitigate molecular cell stress
during freeze/thaw process in cord blood
stem cells, T cells, others
Serum-free, protein-free, animal-origin free;
high quality ingredients; US FDA Master File
√
√
√

28. BioLife Solutions Investor Presentation : May 2023
28
HypoThermosol® Storage Media - Proprietary
Optimized for hypothermic (2-8°C) storage and
shipping of cells and tissues
Enables multiple days of cell and tissue storage for
transport of source material and manufactured cell
products throughout the world
Serum-free, protein-free, animal-origin free;
high quality ingredients; US FDA Master File
√
√
√

29. BioLife Solutions Investor Presentation : May 2023
29
Sexton Cell Processing Tools
Patented CellSeal® Closed-System Cryogenic Vials
design to reduce contamination risk, offer uniform
freezing & thawing profiles, and maximize recovery
Signata CT-5™ brings traditionally manually performed
processes under a higher level of control to protect
products from loss or contamination
Stemulate® human platelet lysate is ethically
sourced and heparin-free, with minimal lot-to-
lot variability through large batch production
√
√
√
Embedded in 3
approved therapies
and 140 clinical trials

30. BioLife Solutions Investor Presentation : May 2023
30
Marquee Direct Customers

31. BioLife Solutions Investor Presentation : May 2023
31
Force Multiplier Customers
CLINICAL CENTERS
—————————
CMO & CDMO
—————————

32. BioLife Solutions Investor Presentation : May 2023
32
Cell Processing Tools & Services Embedded in 14
Approved Therapies Selected Disclosures
Some of the above use biopreservation media and Sexton cell processing tools

33. BioLife Solutions Investor Presentation : May 2023
33
Storage & Storage Services Platform

34. BioLife Solutions Investor Presentation : May 2023
34
evo® Cold Chain Management Platform
-196° C -80° C
• Embedded in >100 Clinical Trials
• Q1 2023 shipments up >100% over Q1 2022
Built in monitoring systems minimize traceability
challenges during shipment and seamlessly
scale to commercial volumes
evoIS™ Web Application provides continual visibility
to the location*, status and condition of time and
temperature sensitive biologic materials
evo® Smart Shippers expand commercial reach
of high-value regenerative medicines, with
proprietary design minimizing heat exchange
within the system ensuring optimal performance
√
√
√
*excluding above 10,000 ft MSL

35. BioLife Solutions Investor Presentation : May 2023
35
SciSafe® Biologic Storage Services
Strategically located facilities in the US & EU offer
storage conditions from 70°C to -196°C, 24/7
monitoring, risk management procedures, and an
electronic inventory system with near real-time visibility
Class-defining customer service 24/7/365
Services range from complete customized fully
cGMP compliant outsourced biostorage
solutions to hybrid-onsite sample management
√
√
√

36. BioLife Solutions Investor Presentation : May 2023
36
Freezers & Thaw Systems Platform

37. BioLife Solutions Investor Presentation : May 2023
37
Cryogenic Freezers Platform
Programmable controlled-rate freezers with six-probe
monitoring offer exceptional temperature uniformity,
customizable freezing programs and the ability to
monitor conditions in real time
High-capacity controlled rate freezers designed
to support the eventual transition from
autologous to allogeneic cell therapies
Isothermal liquid nitrogen freezers with patented
jacket technology provide completely dry storage
area with industry-leading temperature uniformity
√
√
√

38. BioLife Solutions Investor Presentation : May 2023
38
Stirling™ Ultra Low Temperature (ULT) Freezers
Compressor-free; patented Stirling engine
design; less electrical demand, heat
generation and noise pollution
Highly cost efficient with extremely tight
temperature regulation with lower cost of ownership
than the standard compressor-based system
Upright, benchtop, undercounter and portable
ultra low temperature freezer models with
optimized rack and tray configurations
√
√
√

39. BioLife Solutions Investor Presentation : May 2023
39
ThawSTAR® Automated, Water-Free Thawing
ThawSTAR® technology operates on sensor-based
thawing algorithms designed to provide for
consistent thawing outcomes.
Pre-thaw transporter systems support short-term
transport or processing that maintains pre-thaw
temperature stability.
Convenient, standardized and reproducible
thawing of biologics frozen in vials and bags,
reducing risks of over-thawing and contamination
√
√
√

40. BioLife Solutions Investor Presentation : May 2023
40
Leadership & Investment Thesis

41. BioLife Solutions Investor Presentation : May 2023
41
Leadership Team
Mike Rice – Chairman & Chief Executive Officer
BS Bus Admin; 16+ years as BLFS CEO; chief visionary of
BLFS market opportunities, branding, marketing strategies; 18
years medical device sales, sales management, marketing;
patient monitoring, defibrillators, implantable CRM, hearing
devices, LAN/WAN; 5 issued and 13 pending patents
Karen Foster – Chief Quality Officer
BS Biological Sciences, MS Zoology, MBA; 25-year career in
quality and manufacturing operations including 13 years VP
Manufacturing Operations and Site Leader at ViaCord, 2 positions
leading 80 member teams; certified Six Sigma Green Belt
Todd Berard – Chief Marketing Officer
BS, Biochemistry, MBA; 16 years marketing including
leadership of marcom, corporate branding, product
marketing, and positioning for Verathon, Physio Control
(MDT), tech startups
Aby J. Mathew, PhD – EVP, Chief Scientific Officer
BS Microbiology, PhD, Cell & Molecular Biology; co-developer of platform
HypoThermosol® and CryoStor ® media; in demand industry thought leader in
biopreservation of cells and tissues for clinical applications; catalyst responsible
for driving regen med market to adopt BLFS clinical grade biopreservation
media; 6 issued and 6 pending patents; numerous journal articles
Troy Wichterman – Chief Financial Officer
BBA, MS Accounting, CPA (inactive); 13 years of experience in
various finance and accounting roles; most recently served as
BioLife’s Vice President, Finance since November 2019; integral in six
acquisitions. Started with BioLife in 2015 with several positions of
increasing responsibility.
Marcus Schulz – Chief Revenue Officer
20+ years experience in strategic business development and
executive sales leadership roles with companies including
Siemens Healthcare, Johnson & Johnson, Abbott Laboratories
and most recently, GE Healthcare, with primary management
of a $1 billion annual revenue strategic account.

42. BioLife Solutions Investor Presentation : May 2023
42
Leadership Team
Sarah Aebersold, J.D. – Global VP, Human Resources
BA Psychology, JD. Joined BioLife in 2020 with over 15
years of HR leadership experience at various companies in
the industries of Biotechnology, Medical Device, Software,
and Healthcare.
Mike Palotta – Global VP, Hardware and Electrical Engineering
BS, Mechanical Engineering, MBA; Led effort to introduce new
products in the Cell Processing platform with Cook Regentec and
Sexton. Held numerous roles at Rolls-Royce Corporation including
development of gas turbine engines, mechanical design, technical
project management, and systems engineering.
Seth Lilly– Global VP, Software Engineering
UCLA Anderson Certified Director with 20+ years experience in
information systems, engineering, and technical leadership roles in
organizations including EPSCoR and Cisco Systems, providing expertise
in modern information system architecture, user experience, and
strategic technology development.
Geraint Phillips – Senior Vice President, Global Operations
BS Physics from Cardiff University, MBA from the University
of South Wales. Former COO of Stirling Ultracold, Geraint has over
20 years of operational executive leadership experience that
includes previous roles at Azenta Life Sciences and PerkinElmer.
Brett Stucker – Global VP, Information Technology
25+ years experience in digital media production, digital
forensics, network design and installation, and IT leadership
supporting 5,000+ users globally in government, public and
private companies, and NGO non-profit endeavors. Industries
include law enforcement, defense, higher
education, aerospace, and biotech manufacturing.
Garrie Richardson – General Manager, Storage Services
With over 15 years of sample management experience, Garrie has
overseen the growth of SciSafe’s business from three refrigerated
chambers to hundreds today. He has intimate, hands-on
experience with all aspects of sample management and is driving
the company to become the global leader in sample management
and integrated cold chain solutions.

43. BioLife Solutions Investor Presentation : May 2023
43
Investment Thesis
Class-defining portfolio of bioproduction tools and services designed to improve
quality and de-risk cell and gene therapy manufacturing and delivery – pure play picks
and shovels
Proprietary biopreservation media embedded in > 630 customer clinical applications;
Sexton tools embedded in 140 clinical trials; each could generate $500K - $2mm
annual revenue post approval and scale up
Thousands of sticky cell processing customers across the regenerative medicine
landscape to leverage for cross-selling revenue synergies
Exploring strategic alternatives for freezer businesses to improve financial profile and
focus portfolio on high margin, recurring revenue streams
Anticipating 70% recurring, high-margin revenue in 2025

44. BioLife Solutions Investor Presentation : May 2023
44
Supplemental Financial
Information

45. BioLife Solutions Investor Presentation : May 2023
45
Q1 2023 Adjusted Financial Results (non-GAAP)
Three Months Ended
($’s in millions, except percentage
and basis point figures)
March 31, 2023 March 31, 2022 Change % Change
Revenue 37.7 36.2 1.5 4%
Gross Margin % (adj.) 37.2% 32.5% 470 bps n/a
OPEX (adj.) 25.5 20.1 5.4 27%
Operating Profit (adj.) (11.4) (8.3) (3.1) (37%)
Net Income (adj.) (11.4) (8.4) (3.1) (36%)
EBITDA (adj.) (1.9) (1.1) (0.8) 68%

46. BioLife Solutions Investor Presentation : May 2023
46
Cap Table (05/04/2022)
(,000) Shares Options/RSAs Total
Directors & Officers 780 1,297 2,077
Affiliates 15,510 - 15,510
Other 27,166 1,508 28,674
Total 43,456 2,805 46,261

47. BioLife Solutions Investor Presentation : May 2023
47
GAAP to Non-GAAP
Financial Information

48. BioLife Solutions Investor Presentation : May 2023
48
GAAP to Non-GAAP Gross Profit
Three Months Ended
March 31,
(In thousands) 2023 2022
GAAP GROSS PROFIT $ 13,306 $ 10,285
GAAP GROSS MARGIN 35 % 28 %
ADJUSTMENTS TO GROSS PROFIT:
Intangible asset amortization 733 1,489
ADJUSTED GROSS PROFIT $ 14,039 $ 11,774
ADJUSTED GROSS MARGIN 37 % 33 %

49. BioLife Solutions Investor Presentation : May 2023
49
GAAP to Non-GAAP Operating Expenses
Three Months Ended
March 31,
(In thousands) 2023 2022
GAAP OPERATING EXPENSES $ 51,308 $ 44,187
ADJUSTMENTS TO OPERATING EXPENSES:
Cost of product, rental, and service revenue (23,664) (24,446)
Acquisition costs - (11)
Intangible asset amortization (1,459) (2,863)
Loss on disposal of assets (9) (96)
Change in fair value of contingent consideration (720) 3,335
ADJUSTED OPERATING EXPENSES $ 25,456 $ 20,106

50. BioLife Solutions Investor Presentation : May 2023
50
GAAP to Non-GAAP Operating Income
Three Months Ended
March 31,
(In thousands) 2023 2022
GAAP OPERATING LOSS $ (13,605) $ (7,967)
ADJUSTMENTS TO OPERATING LOSS:
Acquisition costs - 11
Intangible asset amortization 1,459 2,863
Loss on disposal of assets 9 96
Change in fair value of contingent consideration 720 (3,335)
ADJUSTED OPERATING LOSS $ (11,417) $ (8,332)

51. BioLife Solutions Investor Presentation : May 2023
51
GAAP to Non-GAAP Net Income
Three Months Ended
March 31,
(In thousands) 2023 2022
GAAP NET LOSS $ (13,714) $ (7,421)
ADJUSTMENTS TO NET LOSS:
Acquisition costs - 11
Intangible asset amortization 1,459 2,863
Loss on disposal of assets 9 96
Change in fair value of contingent consideration 720 (3,335)
Income tax benefit 92 (599)
ADJUSTED NET LOSS $ (11,434) $ (8,385)

52. BioLife Solutions Investor Presentation : May 2023
52
GAAP to Non-GAAP Adjusted EBITDA
Three Months Ended
March 31,
(In thousands) 2023 2022
GAAP NET LOSS $ (13,714) $ (7,421)
ADJUSTMENTS:
Interest expense, net 411 184
Income tax expense (benefit) 92 (599)
Depreciation 1,731 1,653
Intangible asset amortization 1,459 2,863
EBITDA $ (10,021) $ (3,320)
OTHER ADJUSTMENTS:
Share-based compensation (non-cash) 7,363 5,399
Inventory step-up - -
Acquisition costs - 11
Loss on disposal of assets 9 96
Change in fair value of contingent consideration 720 (3,335)
ADJUSTED EBITDA $ (1,929) $ (1,149)

53. BioLife Solutions Investor Presentation : May 2023
53
BioLife Solutions Inc.
3303 Monte Villa Parkway,
Suite 310, Bothell, WA 98021 USA
T +1.866.424.6543 or 425.402.1400
F +1.425.402.1433
E info@biolifesolutions.com
biolifesolutions.com
biolifesolutions.com
For additional questions or comments, please contact:
Mike Rice | Chief Executive Officer
mrice@BioLifeSolutions.com | (425) 686-6003
Troy Wichterman | Chief Financial Officer
twichterman@BioLifeSolutions.com | (425) 402-1400
www.biolifesolutions.com
LHA Investor Relations
www.lhai.com
(310) 691-7100
NASDAQ: BLFS